Legend Biotech (LEGN) Q3 2026 earnings review
Legend Biotech earns a clean profit, but US sales stall
Legend Biotech, the maker of the blood-cancer cell therapy CARVYKTI, proved it can earn a profit from product sales alone even as its main US market stalled. Collaboration revenue rose 35% from a year ago, generating $47 million in operating profit without the one-time partner milestone payment that carried last quarter. Newly appointed chief executive Ingrid Zhang kept the full-year profitability plan intact as international hospital sales jumped 86% to $238 million.
| Collaboration revenue | $353.2M +35% from a year ago, +8% from Q2 |
|---|---|
| CARVYKTI global net trade sales | $710M +36% from a year ago (US +19%, ex-US +86%) |
| Profit, excluding one-offs | $55.6M loss of $18.7M a year ago |
| Full-year profitability outlook | Unchanged $108.4M profit excluding one-offs through nine months |
⚖️ Verdict: 🟢 Bullish
The story got better because product revenue now covers research and commercial costs on its own, and the company settled its leadership search and cleared its next-generation therapy for US trials ahead of schedule. The bad news: US CARVYKTI sales stayed unchanged from last quarter at $472 million, and a $10 million stock-compensation reversal from departed executives flattered the reported operating profit.
The question now is whether flat US sales from the second to the third quarter mark a temporary pause or real pressure from competing antibody drugs in earlier lines of myeloma treatment. Either updated US cancer guidelines will restart domestic sequential growth, or rival off-the-shelf drugs are capping CARVYKTI's share in community clinics. Fourth-quarter US net trade sales will tell.
🐂 Bull Case
Product Sales Now Carry Profit Without Milestone Help
Legend Biotech develops CARVYKTI, a cell therapy for the blood cancer multiple myeloma, in a fifty-fifty partnership with Johnson & Johnson. Last quarter, the company's first operating profit relied on a $56 million partner milestone payment. In the third quarter, the cell therapy maker earned $46.8 million in operating income and $55.6 million in profit excluding one-offs with no milestone boost.
- Collaboration revenue from CARVYKTI: $353.2 million, up 34.9% from a year ago and 8.3% from last quarter
- Research and development costs: 26.5% of revenue, down 15.1 percentage points from a year ago by our math
- Selling and distribution costs: 15.3% of revenue, down 4.0 percentage points from a year ago by our math
The profit held up because research costs dropped by $17.9 million as "the patient dosing phases of major trials substantially concluded", the company said. Collaboration revenue also cleared collaboration cost of sales by $206.2 million, so product demand now covers ongoing trials and commercial staff on its own.
What to watch: fourth-quarter research and development spending as new trials start in the United States. If research costs stay near $95 million while product sales grow, the business can fund its own pipeline without new share sales.
International Sales Carry CARVYKTI Growth
Total CARVYKTI net trade sales — the amount hospitals pay Johnson & Johnson for the therapy — reached $710 million, up 36% from a year ago and 8.1% from last quarter by our math. International markets provided every dollar of the increase over the second quarter.
Sales outside the United States rose 86% from a year ago to $238 million, and jumped 28.6% from last quarter's $185 million by our math. The partners added 25 certified hospitals during the quarter to reach 373 treatment sites across 20 markets. Because newly certified overseas hospitals take several months to treat their first patients, the 79 sites added over the past two quarters are now turning into infusions.
What to watch: the number of certified hospitals outside the United States at year-end. Continued additions above 20 sites per quarter would show international demand still has room to make up for slower domestic growth.
FDA Clears Next-Generation Therapy Ahead of Schedule
Today's cell therapies require harvesting a patient's blood cells, engineering them in a factory, and infusing them back weeks later. Legend Biotech is developing LB2501, an experimental therapy for B-cell blood cancers designed to "generate CAR-T cells directly within the patient following a single intravenous infusion", the company said.
United States regulators cleared LB2501 to begin human trials during the third quarter, ahead of management's fourth-quarter target. The board also resolved a leadership question by naming Ingrid Zhang as permanent chief executive on September 15, ending Alan Bash's interim tenure so he could return to running CARVYKTI.
What to watch: updated human trial data for LB2501 at the American Society of Hematology meeting in December 2026. Durable cancer responses without severe immune side effects would validate the direct-infusion approach.
🐻 Bear Case
US Sales Stalled From Last Quarter
"Together, the promising early line data and updated NCCN guidelines preferring CAR-T ahead of other BCMA-directed therapies well positions CARVYKTI to potentially gain market share in the second- and third-line setting," chief executive Ingrid Zhang said. The National Comprehensive Cancer Network (NCCN), which writes US cancer treatment standards, now recommends that myeloma patients be "referred to a T-cell therapy capable center at first relapse".
Yet United States net trade sales did not grow this quarter. Domestic sales were $472 million, unchanged from $472 million in the second quarter by our math. Yearly US growth slowed to 19%, down from 32% in the second quarter, 36% in the first quarter, and 53% a year ago.
That stall explains why management refused last quarter to repeat its promise of quarter-over-quarter growth in the United States. Five-year trial data showed half of earlier-line patients stayed cancer-free, but off-the-shelf antibody drugs called bispecifics remain easier for community doctors to give than a custom cell infusion.
What to watch: fourth-quarter US CARVYKTI net trade sales, which include an extra selling week. If domestic revenue fails to rise meaningfully above $472 million even with an extra week, earlier-line demand in the United States is hitting a ceiling.
Executive Departures Created a One-Time Profit Boost
Legend Biotech's reported operating profit benefited from an unusual accounting credit tied to staff turnover. Following the departure of the former chief executive and research chief earlier this year, administrative expenses fell by $19.9 million from a year ago to $14.8 million, dropping 8.6 percentage points as a share of revenue by our math.
The company said the drop came from "the forfeiture of certain unvested equity awards and the resulting reversal of previously recognized compensation expense". Across the whole company, share-based compensation was a negative $9.6 million expense, compared with a $15.0 million cost a year ago and $17.3 million last quarter. Without that credit, by our math administrative expenses were $24.4 million and operating income was $37.2 million.
What to watch: fourth-quarter administrative expenses and share-based compensation now that new chief executive Ingrid Zhang is in place. A return of stock compensation to around $15 million will trim reported operating margins.
Risks this quarter didn't answer
Three standing questions about profitability margins, patient mix, and future trials were not readable in the third-quarter news release and await the conference call or filing.
- Gross margin on net product sales: management previously forecast a dip to the lower-50% range for the third quarter due to outpatient mix; the release shows collaboration gross margin held at 58.4% by our math, but does not break out the net product sales metric.
- Earlier-line patient share: the company targets three-quarters of CARVYKTI orders coming from second- through fourth-line patients in 2026, up from over 70% last quarter, and gave no figure in the release.
- Frontline trial readouts: timing for the CARTITUDE-5 and CARTITUDE-6 trials in newly diagnosed patients, previously set for 2026 or 2027, received no update.
💲 Other KPIs
Fell by $112.3 million from last quarter's $156.4 million by our math, down from $319.1 million at the end of 2025. This liability is money Johnson & Johnson advanced to build the business, which it recoups from Legend Biotech's half of CARVYKTI profits. That paydown explains why operating cash flow was negative $35.9 million despite positive net income.
Total cash, cash equivalents and bank time deposits declined by $112.1 million from $964.6 million in the second quarter by our math. The decrease mirrors the operating cash outflow, capital investments, and $50.7 million used in financing activities as the cell therapy group paid down its partner advances.
Diluted weighted average shares rose 8.4% from 369.3 million a year ago and 3.3% from 387.6 million in the second quarter by our math. The increase reflects the 15.4 million ordinary shares sold in June's public offering plus employee stock options that now count toward dilution because the company is profitable.
🔮 Guidance
Unchanged. Chief executive Ingrid Zhang reaffirmed the plan for "delivering sustained profitability" in 2026, which the company defines as positive net income excluding one-offs. With $55.6 million earned in the third quarter, nine-month profit excluding one-offs reached $108.4 million. By our math, the fourth quarter would have to lose more than $108.4 million to miss the full-year goal, making the annual target secure.
❓ Key Questions
Why did US CARVYKTI sales stop growing from Q2?
United States net trade sales stayed at $472 million for a second straight quarter even after cancer guidelines recommended earlier referrals. Investors need to know whether competing bispecific antibody drugs, hospital staffing limits, or order timing caused the stall.
What was gross margin on net product sales?
Management previously warned that third-quarter gross margin on net product sales would drop to the lower-50% range as more patients received treatment outside hospital wards. Collaboration gross margin stayed at 58.4% by our math, leaving the underlying product margin unexplained.
How close is CARVYKTI to the 75% earlier-line goal?
Legend Biotech set a 2026 target to get three-quarters of its orders from patients in their second through fourth lines of treatment, up from over 70% last quarter. The release omitted the third-quarter figure.
Will operating cash flow turn positive in 2027?
Only $44.1 million of Johnson & Johnson's interest-bearing funding advance remains on the balance sheet, down from $319.1 million at year-end. Once the final balance is settled in the fourth quarter, investors want to know how much reported profit will convert into cash.